Skip to content

DMT: all studies

Page 132 of 160: studies 1,311 to 1,320 of 1,594, newest first. Back to the DMT overview

Research

The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization

Frontiers in Pharmacology 2016 Petra Bokor, Ede Frecska, Michael Winkelman

Ayahuasca is an Amazonian psychoactive brew of two main components. Its active agents are β-carboline and tryptamine derivatives. As a sacrament, ayahuasca is still a central element of many healing ceremonies in the Amazon Basin and its ritual consumption has become common among the mestizo populations of South America. Ayahuasca use amongst the indigenous people of the Amazon is a form of...

DOI: 10.3389/fphar.2016.00035/full (opens in new tab) Full text (opens in new tab) Psychedelics Traditional medicine Mental health Ethnobotany

Effects of Long-Term Ayahuasca Administration on Memory and Anxiety in Rats

PLoS One December 30, 2015 Vanessa Manchim Favaro, Maurı́cio Yonamine, Juliana Carlota Kramer Soares et al. 33 citations

Ayahuasca is a hallucinogenic beverage that combines the action of the 5-HT2A/2C agonist N,N-dimethyltryptamine (DMT) from Psychotria viridis with the monoamine oxidase inhibitors (MAOIs) induced by beta-carbonyls from Banisteriopsis caapi. Previous investigations have highlighted the involvement of ayahuasca with the activation of brain regions known to be involved with episodic memory,...

Glokalizace ayahuasky v ČR a možnosti jejího terapeutického využití v místních podmínkách

Anthropologia integra December 15, 2015 Miroslav Horák, Romana Lukášová, Šárka Vosáhlová 6 citations

Z ayahuasky, klíčového prvku tradiční domorodé medicíny peruánské Amazonie, se stal globální fenomén. Sezení, během něhož je užívána tato psychoaktivní látka, lze v současné době absolvovat nejen v prostředí jihoamerického deštného pralesa, ale také v České republice. Vzhledem k tomu, že je v ČR ayahuasca pro svůj obsah N, N-dimethyltriptaminu dle nařízení vlády č. 463/2013 Sb., O seznamech...

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression

Journal of Clinical Psychopharmacology December 11, 2015 Rafael Faria Sanches, Flávia de Lima Osório, Rafael G. Dos Santos et al. 468 citations

Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in...

Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities

Psychopharmacology November 27, 2015 Joaquim Soler, Matilde Elices, Alba Franquesa et al. 212 citations

BackgroundAyahuasca is a psychotropic plant tea used for ritual purposes by the indigenous populations of the Amazon. In the last two decades, its use has expanded worldwide. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine-oxidase-inhibiting properties. Acute administration induces an introspective dream-like...

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.

Toxicology Letters November 17, 2015 Julia Dinger, Campbell Woods, Simon D. Brandt et al.

New psychoactive substances (NPS) are not tested for their cytochrome P450 (CYP) inhibition potential before consumption. Therefore, this potential was explored for tryptamine-derived NPS (TDNPS) including alpha-methyl tryptamines (AMTs), dimethyl tryptamines (DMTs), diallyl tryptamines (DALTs), and diisopropyl tryptamines (DiPTs) using test substrates preferred by the Food and Drug...

Acute Biphasic Effects of Ayahuasca

PLoS One September 30, 2015 Eduardo Ekman Schenberg, João Felipe Morel Alexandre, Renato Filev et al. 115 citations

Ritual use of ayahuasca, an amazonian Amerindian medicine turned sacrament in syncretic religions in Brazil, is rapidly growing around the world. Because of this internationalization, a comprehensive understanding of the pharmacological mechanisms of action of the brew and the neural correlates of the modified states of consciousness it induces is important. Employing a combination of...

Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.

Drug and Alcohol Dependence September 3, 2015 Joseph J Palamar, Silvia S Martins, Mark K Su et al.

Background: In recent years, there has been an increase in emergence and use of novel psychoactive substances (NPS) in the US and worldwide. However, there is little published epidemiological survey data estimating the prevalence of use in the US. Method: Data on self-reported NPS use came from the National Survey of Drug Use and Health (2009-2013), a national representative sample of...

DOI: 10.1016/j.drugalcdep.2015.08.028 (opens in new tab) Full text (opens in new tab) Humans Substance-related disorders Tryptamines N,N-Dimethyltryptamine +18

The Root of All Things

River teeth September 1, 2015 Nathan Thornburgh

The Root of All Things Nathan Thornburgh (bio) Halfway through our hour-long Skype call, Carlos Tanner warns me that he is going to “cross over.” He means that our conversation is about to leap from things that make sense in this world—how his new baby is sleeping, how many students are enrolling in his school—into things that only make sense if you are very deep in the world of ayahuasca, a...

Psilocybin, psychological distress, and suicidality

Journal of Psychopharmacology September 1, 2015 Peter S. Hendricks, Matthew W Johnson, Roland R. Griffiths 107 citations

Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid diethylamide (LSD), mescaline, peyote or San Pedro, or psilocybin—was associated with a significantly reduced likelihood of past month psychological distress (weighted OR = . 81 (. 72–. 91)), past year suicidal thinking (weighted OR = . 86 (. 78–....

DOI: 10.1177/0269881115598338 (opens in new tab) Full text (opens in new tab) Psilocybin Psychological distress Hallucinogen Clinical psychology +1